SEC filing · 8-K

Travere Therapeutics, Inc.: Executive or director change

Travere Therapeutics announced that Bradley L. Campbell will succeed Dr. Eric Dube as President and Chief Executive Officer effective December 1, 2026.

Filed September 21, 2026

Neutral news

What happened

Dr. Eric Dube will step down from his role as President, Chief Executive Officer, and director on December 1, 2026.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Travere Therapeutics, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.